Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data
Open Access
- 17 April 2014
- journal article
- review article
- Published by Springer Nature in British Journal of Cancer
- Vol. 111 (1) , 33-45
Abstract
Erythropoiesis-stimulating agents (ESAs) reduce the need for red blood cell transfusions; however, they increase the risk of thromboembolic events and mortality. The impact of ESAs on quality of life (QoL) is controversial and led to different recommendations of medical societies and authorities in the USA and Europe. We aimed to critically evaluate and quantify the effects of ESAs on QoL in cancer patients. We included data from randomised controlled trials (RCTs) on the effects of ESAs on QoL in cancer patients. Randomised controlled trials were identified by searching electronic data bases and other sources up to January 2011. To reduce publication and outcome reporting biases, we included unreported results from clinical study reports. We conducted meta-analyses on fatigue- and anaemia-related symptoms measured with the Functional Assessment of Cancer Therapy-Fatigue (FACT-F) and FACT-Anaemia (FACT-An) subscales (primary outcomes) or other validated instruments. We identified 58 eligible RCTs. Clinical study reports were available for 27% (4 out of 15) of the investigator-initiated trials and 95% (41 out of 43) of the industry-initiated trials. We excluded 21 RTCs as we could not use their QoL data for meta-analyses, either because of incomplete reporting (17 RCTs) or because of premature closure of the trial (4 RCTs). We included 37 RCTs with 10 581 patients; 21 RCTs were placebo controlled. Chemotherapy was given in 27 of the 37 RCTs. The median baseline haemoglobin (Hb) level was 10.1 g dl–1; in 8 studies ESAs were stopped at Hb levels below 13 g dl–1 and in 27 above 13 g dl–1. For FACT-F, the mean difference (MD) was 2.41 (95% confidence interval (95% CI) 1.39–3.43; Pn=6108) in all cancer patients and 2.81 (95% CI 1.73–3.90; Pn=4697) in patients receiving chemotherapy, which was below the threshold (3) for a clinically important difference (CID). Erythropoiesis-stimulating agents had a positive effect on anaemia-related symptoms (MD 4.09; 95% CI 2.37–5.80; P=0.001; 14 studies, n=2765) in all cancer patients and 4.50 (95% CI 2.55–6.45; Pn=2436) in patients receiving chemotherapy, which was above the threshold (4) for a CID. Of note, this effect persisted when we restricted the analysis to placebo-controlled RCTs in patients receiving chemotherapy. There was some evidence that the MDs for FACT-F were above the threshold for a CID in RCTs including cancer patients receiving chemotherapy with Hb levels below 12 g dl–1 at baseline and in RCTs stopping ESAs at Hb levels above 13 g dl–1. However, these findings for FACT-F were not confirmed when we restricted the analysis to placebo-controlled RCTs in patients receiving chemotherapy. In cancer patients, particularly those receiving chemotherapy, we found that ESAs provide a small but clinically important improvement in anaemia-related symptoms (FACT-An). For fatigue-related symptoms (FACT-F), the overall effect did not reach the threshold for a CID.Keywords
This publication has 101 references indexed in Scilit:
- Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancerBritish Journal of Cancer, 2012
- Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulationBritish Journal of Cancer, 2011
- Erythropoietin receptor contributes to melanoma cell survival in vivoOncogene, 2011
- Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomesBritish Journal of Cancer, 2010
- Effect of treatment with epoetin-β on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patientsBritish Journal of Cancer, 2008
- Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated AnemiaJAMA, 2008
- Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancerGynecologic Oncology, 2008
- Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trialBritish Journal of Cancer, 2006
- Individual patient‐ versus group‐level data meta‐regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly headStatistics in Medicine, 2002
- Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancerBritish Journal of Cancer, 1999